BrainEver Secures €33 Million in Series B Funding to Advance ALSClinical Program

Paris, July 3, 2025 – BrainEver, a biotechnology company focused on neurodegenerative

diseases, today announced the successful completion of its €33 million Series B financing

round. This funding will support the launch of the company’s first clinical trial in Europe for

its lead therapeutic candidate targeting amyotrophic lateral sclerosis (ALS).

The round was co-led by Critical Path Ventures and the European Innovation Council (EIC),

with continued support from existing investors Ibionext and Relyens. In a highly challenging

environment for biotech financing, this successful raise reflects strong investor confidence in

BrainEver’s therapeutic potential, the robustness of its science, and the clinical relevance of

its approach across Europe.

BrainEver’s innovation is rooted in decades of research led by Professor Alain Prochiantz at

the Collège de France and the French National Centre for Scientific Research (CNRS).

Pioneering a New Approach to Neuronal Rejuvenation

BrainEver is developing a novel platform based on neuronal reprogramming, aimed at halting the progression of neurodegenerative diseases by reactivating the intrinsic repair capabilities of affected neurons. This approach offers a transformative path forward for diseases such as ALS, Parkinson’s disease, and sensory degenerations, where current treatment options remain limited or nonexistent.

A Phase I/II clinical trial in ALS is set to begin by the end of 2025 at Utrecht University in the

Netherlands, a leading European center for ALS research and care. This major milestone

marks BrainEver’s entry into clinical-stage development and could bring meaningful hope to

thousands of patients currently without therapeutic alternatives.

Broad-Based Support from the Scientific and Medical Community

The funding round also included participation from individual investors—patients, physicians, scientists, and entrepreneurs—via the Tudigo platform, underscoring broad support for BrainEver’s vision.

The company was co-founded by Bernard Gilly, a seasoned healthtech entrepreneur, and

Professor Alain Prochiantz, an internationally recognized neuroscientist and professor at the

Collège de France. Their shared mission: to translate fundamental neuroscience into

breakthrough therapies.

Bernard Gilly, Co-founder and CEO of BrainEver, stated: “This funding is a pivotal step

that enables us to initiate our first clinical trial and accelerate validation of our ALS therapy.

Our approach is designed to target all forms of ALS, whether genetic or sporadic. In today’s

bare markets, this round demonstrates the strength of our science and the credibility of our

clinical strategy. We are deeply grateful to the investors who share our vision.”

Professor Alain Prochiantz, Co-founder and Chief Scientific Officer, added: “This raise is

a strong endorsement of the scientific foundation behind BrainEver, which is the result of

decades of fundamental research. It marks a crucial step in translating the concept of neuronal rejuvenation into a viable clinical therapy.”